Aquestive Therapeutics (NASDAQ:AQST) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01), Zacks reports. The firm had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same quarter in the prior year, the company earned ($0.03) EPS.

Aquestive Therapeutics Price Performance

Aquestive Therapeutics stock traded down $0.40 during midday trading on Tuesday, hitting $4.76. 3,475,844 shares of the company were exchanged, compared to its average volume of 1,754,294. The company has a market cap of $432.99 million, a PE ratio of -13.59 and a beta of 2.82. The company's fifty day moving average price is $4.90 and its 200-day moving average price is $3.82. Aquestive Therapeutics has a fifty-two week low of $1.52 and a fifty-two week high of $6.23.

Analyst Ratings Changes

AQST has been the subject of a number of analyst reports. JMP Securities reissued a "market outperform" rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Friday, October 25th. Finally, Leerink Partners increased their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $8.83.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.